Bluejay Diagnostics Q3 net loss widens to $3.0M; cash $13.3M; FDA submission planned H1 2023

Bluejay Diagnostics, Inc.

2022-Q3 EPS reported -$0.34 revenue$249,040

Net loss for Q3 2022 was $3.0M ($0.15 per share) vs $1.2M ($0.11 per share) in Q3 2021.
Cash and cash equivalents at Sep 30, 2022: $13.3M, down from $19.0M at Dec 31, 2021; cash expected to fund operations for 12 months.
R&D expenses rose to $1.4M in Q3 2022 from $443k in Q3 2021 due to clinical program expansion and scale-up manufacturing.
No product sales in Q3; small non-recurring sale in Q2 2022 generated ~$250k revenue for nine months.
Company plans to submit De Novo application for Symphony IL-6 test with FDA in first half of 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bluejay Diagnostics, Inc. reported nine months ended September 30, 2022 results: net income $6.9 million, EPS $0.34 per share.

Period: nine months ended September 30, 2022
Net income: $6.9 million
EPS: $0.34 per share
Result: reported results

Exact text from the filing

The net loss for the three and nine months ended September 30, 2022 was $3.0 million and $6.9 million, or $0.15 and $0.34 per share, respectively

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Bluejay Diagnostics, Inc. reported quarter ended September 30, 2022 results: net income $3.0 million, EPS $0.15 per share.

Period: quarter ended September 30, 2022
Net income: $3.0 million
EPS: $0.15 per share
Result: reported results

Exact text from the filing

The net loss for the three and nine months ended September 30, 2022 was $3.0 million and $6.9 million, or $0.15 and $0.34 per share, respectively

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Bluejay Diagnostics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-22-070134

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.